このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Syros Pharmaceuticals 将来の成長

Future 基準チェック /36

Syros Pharmaceuticals利益と収益がそれぞれ年間61.1%と60.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に105% 63.9%なると予測されています。

主要情報

60.6%

収益成長率

63.2%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	60.9%
将来の株主資本利益率	104.6%
アナリストカバレッジ	Low
最終更新日	26 Jun 2024

今後の成長に関する最新情報

Recent updates

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 02

Syros Pharma up 18% day after ARK Innovation dumps shares

May 27

Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

May 11

Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

May 07

業績と収益の成長予測

NasdaqGS:SYRS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	151	-37	N/A	N/A	3
12/31/2025	32	-106	N/A	N/A	5
12/31/2024	1	-95	N/A	N/A	5
3/31/2024	7	-144	-104	-104	N/A
12/31/2023	10	-165	-110	-110	N/A
9/30/2023	9	-105	-123	-122	N/A
6/30/2023	9	-95	-127	-126	N/A
3/31/2023	12	-93	-131	-130	N/A
12/31/2022	15	-95	-124	-123	N/A
9/30/2022	23	-114	-116	-115	N/A
6/30/2022	25	-109	-108	-107	N/A
3/31/2022	24	-97	-109	-108	N/A
12/31/2021	23	-87	-101	-100	N/A
9/30/2021	21	-93	-108	-106	N/A
6/30/2021	20	-86	-95	-94	N/A
3/31/2021	18	-81	-81	-80	N/A
12/31/2020	15	-84	-61	-57	N/A
9/30/2020	10	-74	-50	-38	N/A
6/30/2020	7	-74	-48	-34	N/A
3/31/2020	4	-76	-54	-40	N/A
12/31/2019	2	-75	-73	-60	N/A
9/30/2019	2	-74	-68	-63	N/A
6/30/2019	2	-70	-65	-62	N/A
3/31/2019	2	-64	-60	-58	N/A
12/31/2018	2	-62	-42	-40	N/A
9/30/2018	1	-60	-38	-37	N/A
6/30/2018	1	-58	-37	-37	N/A
3/31/2018	0	-57	-35	-34	N/A
12/31/2017	1	-54	N/A	-45	N/A
9/30/2017	1	-50	N/A	-44	N/A
6/30/2017	1	-50	N/A	-43	N/A
3/31/2017	1	-51	N/A	-43	N/A
12/31/2016	0	-51	N/A	-41	N/A
9/30/2016	N/A	-52	N/A	-39	N/A
6/30/2016	N/A	-48	N/A	-35	N/A
3/31/2016	0	-41	N/A	-30	N/A
12/31/2015	0	-35	N/A	-23	N/A
9/30/2015	0	-28	N/A	-18	N/A
12/31/2014	N/A	-16	N/A	-12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SYRS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SYRS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SYRS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SYRSの収益 ( 60.9% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: SYRSの収益 ( 60.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SYRSの自己資本利益率は、3年後には非常に高くなると予測されています ( 105 %)。

Syros Pharmaceuticals 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Price target decreased by 16% to US$21.25

Price target decreased by 16% to US$21.25

Recent updates

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Director exercised options and sold US$72k worth of stock

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

New major risk - Share price stability

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Price target decreased by 16% to US$21.25

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Price target decreased by 16% to US$21.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 10% to US$26.50

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Price target decreased to US$25.40

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Consensus revenue estimates fall by 11%

Insufficient new directors

Consensus forecasts updated

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Consensus forecasts updated

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Consensus forecasts updated

Consensus estimates of losses per share improve by 11%

Price target decreased to US$14.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Syros Pharmaceuticals Is A Buy As New Trials Start

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Syros Pharma up 18% day after ARK Innovation dumps shares